Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Dedicated multidisciplinary oligometastatic breast cancer clinic (OMBCC) as a platform for standardized decision-making and real-world evidence generation.

Bayan Malakouti-Nejad, Nathalie LeVasseur, Elizaveta Vasilyeva et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13614

e13614 Background: Management of de novo oligometastatic breast cancer remains controversial, where randomized trials are...

Updated overall survival results from a randomized phase III trial of non–cross-resistant adjuvant chemotherapy plus endocrine therapy versus endocrine therapy alone in HR+/HER2−/lymph node–positive breast cancer with residual disease following neoadjuvant chemotherapy (NCT01019616).

Yang Yang, Zhaoqing Fan, Yingjian He et al. Jun 01, 2026 pp. 506-506 10.1200/jco.2026.44.16_suppl.506

506 Background: Patients with HR+/HER2−, node-positive breast cancer and residual disease after neoadjuvant chemotherapy (...

Multi-modal AI foundation models approach for diagnosis of myelodysplastic syndromes across whole bone marrow aspirate and biopsy slides.

Palak Dave, Ling Zhang, Joseph Pierce et al. Jun 01, 2026 pp. 6571-6571 10.1200/jco.2026.44.16_suppl.6571

6571 Background: Morphologic diagnosis of myelodysplastic syndromes (MDS) from bone marrow aspirates and biopsies is subje...

Tumor-agnostic ctDNA methylation profiling as an enabler of preoperative risk stratification and pathological response assessment in hepatocellular carcinoma.

Shi-Yu Zhang, De-Zhen Guo, Zhi-Xi Su et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16291

e16291 Background: Clinical management of hepatocellular carcinoma (HCC) is becoming increasingly complex, encompassing cu...

Incidence of arterial and venous vascular complications after radiotherapy for head and neck cancer: A systematic review and meta-analysis.

Anchu Ann Vincent, Syed Muhammad Ahsan, Bhavani Gangineni et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18104

e18104 Background: Advances in radiotherapy (RT) have improved locoregional control and survival in head and neck cancer (...

Burden of renal cell carcinoma: A population-based real-world study of incidence, prevalence, and demographic disparities.

Faiqa Amin, Madho Mal, Danielle Uibel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16530

e16530 Background: Renal cell carcinoma (RCC) is the most common primary malignancy of the kidney and contributes substant...

Yield and clinical utility of peritoneal cytology in patients with locally advanced gallbladder carcinoma undergoing staging laparoscopy.

Shraddha Patkar, Aastha Garg, Mahesh Goel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16225

e16225 Background: Gallbladder cancer (GBC) is an aggressive malignancy with a high incidence in India, where most patient...

Exercise and cardiovascular risk among breast cancer patients.

Erika Libiar Estrada, Aileen Baecker, Jose Pio et al. Jun 01, 2026 pp. 12022-12022 10.1200/jco.2026.44.16_suppl.12022

12022 Background: Breast cancer is the most common cancer among U.S. females, accounting for 15% of new diagnoses. As surv...

Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with relapsed or refractory (R/R) Ewing sarcoma and chondrosarcoma.

Lu Xie, Jie Zang, Yuwei Zhao et al. Jun 01, 2026 pp. 11510-11510 10.1200/jco.2026.44.16_suppl.11510

11510 Background: The prognosis for R/R sarcoma remains dismal with limited effective treatment options. YL201 is a B7H3-t...

Evidence of clonal stability in a 5-year longitudinal prospective cohort of cancer survivors with serial NGS analysis.

Anmol Goyal, Sujata Patil, Salendra Singh et al. Jun 01, 2026 pp. 10562-10562 10.1200/jco.2026.44.16_suppl.10562

10562 Background: Hematopoietic stem and progenitor cells with preleukemic mutations (mut n...

Gut microbiota dynamics of antibiotic fecal microbiota transplantation in esophageal and gastric cancer patients treated with immune checkpoint inhibitors: Preliminary results from the Biorich2 study.

Shotaro Yamaguchi, Yuri Yoshinami, Hirokazu Shoji et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16030

e16030 Background: Despite advances in immune checkpoint inhibitor (ICI)–based therapy, outcomes for patients with unresec...

Safety, efficacy, and pharmacokinetics of XNW28012, a tissue factor antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor (TOP1i) payload, in patients with advanced solid tumors: Results from a phase I/II study.

Miaoyan Wei, Si Shi, Jian Zhang et al. Jun 01, 2026 pp. 3040-3040 10.1200/jco.2026.44.16_suppl.3040

3040 Background: Tissue factor (TF) is overexpressed in a broad range of solid tumors including pancreatic ductal adenocar...

A first-of-its-kind multi-omic assay using lipids and proteins to identify early-stage ovarian cancer in symptomatic individuals.

Abigail McElhinny, Rachel Culp-Hill, Brendan Giles et al. Jun 01, 2026 pp. 5552-5552 10.1200/jco.2026.44.16_suppl.5552

5552 Background: Ovarian cancer (OC) is often diagnosed at advanced stages, leading to one of the highest mortality rates...

Personalized tumor-informed ctDNA monitoring for recurrence in high-risk locally advanced gastrointestinal stromal tumor.

Zhidong Gao, Baosen Cheng, Shuya Yang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23514

e23514 Background: Gastrointestinal stromal tumor (GIST) is the most prevalent mesenchymal neoplasm of the gastrointestina...

Next-generation sequencing–based mutation profiling in solid tumors: A study from a north Indian tertiary care center.

Mohammad Imam Ather, Sergey Kamishov, Aditya J et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15077

e15077 Background: Tumor heterogeneity points to the need for accurate molecular biomarkers to enable early detection, pro...

The Bermuda model: Achieving world-class, equitable, and efficient cancer care in a small island nation.

Ross Jarrett, Shyam Kumar Tanguturi, Anthony Fitzgerald et al. Jun 01, 2026 pp. 11080-11080 10.1200/jco.2026.44.16_suppl.11080

11080 Background: Bermuda is a small island nation that historically faced significant challenges in provision of local ca...

Efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib vs TACE alone in the treatment of non-resectable hepatocellular carcinoma: A systematic review and meta-analysis.

Khawaja Talha Aziz, Muhammad Sohaib Asghar, Ali Noor et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16213

e16213 Background: Hepatocellular carcinoma (HCC) poses a significant global health challenge, with limited treatment opti...

The landscape of oncology clinical trials in Africa over the last three decades (1995-2025).

Rahman Adesoji Olusoji, Edmund Folefac, Jiasheng Wang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23236

e23236 Background: Africa is home not only to 20% of the world’s population but also to the highest human genetic diversit...

Metronomic adjuvant chemotherapy (MACE) in locally advanced oral cavity squamous cell carcinoma post-surgery and adjuvant treatment (MACE postop): A phase III randomized controlled trial.

Pankaj Chaturvedi, Vanita Noronha, Shwetabh Sinha et al. Jun 01, 2026 pp. 6002-6002 10.1200/jco.2026.44.16_suppl.6002

6002 Background: The role of maintenance systemic therapy following definitive surgery and adjuvant treatment in locally a...

Trends in utilization and inpatient outcomes of minimally invasive colectomy for colorectal cancer in the United States, 2018–2023.

Emi Hearn, Qasim Shawesh, Daniel Thomas Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23195

e23195 Background: Use of minimally invasive surgery (MIS) for colorectal cancer (CRC) resection has expanded rapidly, wit...

Adjuvant (Ad) and neoadjuvant (NAd) strategies in higher risk hormone receptor–positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC): Moroccan real-world outcomes.

Hassan Abdelilah Tafenzi, Youssef AIT Takniouine, Farah Choulli et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12735

e12735 Background: In low- and middle-income countries, many higher-risk HR+/HER2- EBC patients (pts) often undergo primar...

Population-level trends in breast cancer incidence, staging, and mortality in Armenia.

Ani Arzoumanian, Sione Markarian, Emma Mastro et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22581

e22581 Background: Armenia, an Upper-Middle Income Country in the South Caucasus, has one of the highest breast cancer mor...

Using artificial intelligence (AI) and retrieval-augmented generation (RAG) to identify patient-reported symptoms post-ambulatory surgery for cancer.

Jennifer R. Cracchiolo, Thomas M. Atkinson, Aleksandr Petrov et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18003

e18003 Background: As ambulatory procedures become commonplace in oncology, post-surgical remote symptom monitoring (RSM)...

Clinico-genomic landscape and prognostic impact of APC/CTNNB1 oncogenic alterations in non–small cell lung cancer.

Leonardo Brunetti, Valentina Santo, Eleonora Gariazzo et al. Jun 01, 2026 pp. 8552-8552 10.1200/jco.2026.44.16_suppl.8552

8552 Background: Genomic activation of the WNT/β-catenin pathway via APC loss-of-function or activating CTNNB1 mutations i...

Liposomal irinotecan plus cisplatin/carboplatin as second-line therapy for platinum-sensitive relapsed extensive-stage small cell lung cancer: Interim results of a phase II trial.

Jie Min, LiLi Liu, Ningqiang Ma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20128

e20128 Background: Platinum-sensitive relapsed extensive-stage SCLC represents an unmet medical need, with limited second-...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page